Novo Nordisk A/s

This study tests if a new insulin that is injected just once a week works as well as daily insulins for controlling blood sugar in people with type 2 diabetes. About 586 adults who have never used insulin before will take either the weekly insulin or a daily one for 13 months. Th…

This early-stage study tests a new drug, NNC0581-0001, in 48 adults with fatty liver and possible liver inflammation. Participants receive either the drug or a placebo as a monthly injection for three months. The main goal is to check safety and how the body processes the medicin…

This early-stage study tests a new medicine called coramitug in 14 people with ATTR-CM, a heart condition caused by abnormal protein deposits. The drug is designed to bind to and help remove these deposits from the heart. Researchers will use special PET/CT scans to see how the d…

This study tests whether UBT251 is safe and helps people with overweight or obesity lose weight. About 333 adults will receive either the drug or a placebo. The main goal is to measure side effects and weight change over time.

This study tests whether combining two experimental drugs (cagrilintide and NNC0480-0389) causes fewer stomach side effects like nausea and vomiting than cagrilintide alone. About 100 women with overweight or obesity will receive both combos at different times. The goal is to see…

This early-stage study tests a new drug called NNC0537-1482 in 36 adults with heart failure. The main goal is to check if the drug is safe and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor the doctors k…

This study looks at how long you need to fast and whether temporarily stopping GLP-1 medications (like liraglutide or semaglutide) affects how much food stays in your stomach. Researchers will measure stomach emptiness after a high-fat meal in 75 people with obesity who are alrea…